HC Wainwright & Co. Maintains Buy on Axsome Therapeutics, Lowers Price Target to $180
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has maintained its Buy rating on Axsome Therapeutics (NASDAQ:AXSM) but lowered the price target from $190 to $180.

August 06, 2024 | 11:08 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
HC Wainwright & Co. has maintained its Buy rating on Axsome Therapeutics but lowered the price target from $190 to $180.
The maintained Buy rating suggests continued confidence in Axsome Therapeutics' prospects, but the lowered price target indicates a slightly more conservative outlook. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100